Hypermarcas (OTCMKTS:HYPMY – Get Free Report) saw an uptick in trading volume on Tuesday. 102,494 shares changed hands during trading, an increase of 117% from the previous session’s volume of 47,293 shares. The stock last traded at $5.36 and had previously closed at $5.14.
Analysts Set New Price Targets
Separately, Jefferies Financial Group upgraded Hypermarcas to a “strong-buy” rating in a research report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Buy”.
Get Our Latest Research Report on HYPMY
Hypermarcas Stock Performance
The firm’s fifty day simple moving average is $4.58 and its 200 day simple moving average is $4.41. The company has a market capitalization of $3.80 billion, a price-to-earnings ratio of 10.80 and a beta of 0.65. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.86 and a quick ratio of 1.26.
Hypermarcas (OTCMKTS:HYPMY – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.01. Hypermarcas had a net margin of 19.77% and a return on equity of 12.68%. On average, sell-side analysts forecast that Hypermarcas will post 0.51 EPS for the current year.
About Hypermarcas
Hypermarcas SA was a Brazilian consumer-health and pharmaceutical company that later changed its corporate name to Hypera SA The company was established as a diversified consumer-products business and, over time, shifted its focus toward pharmaceuticals and healthcare products.
Hypera develops, manufactures and markets prescription medicines, generic and branded-generic drugs, over-the-counter products, vitamins and nutritional supplements. Its portfolio has included well-known Brazilian consumer-health brands such as Neosaldina, Doril, Engov, Benegrip and Addera D3, serving categories including pain relief, cold and flu treatment, digestive health and vitamins.
The company’s principal market is Brazil, where its products are distributed through pharmacies, retailers and other healthcare channels.
See Also
- Five stocks we like better than Hypermarcas
- Chip Stocks Are Sliding—Why Is Smart Money Buying?
- Adults Are Fueling a Toy Boom—These 4 Stocks Could Cash In
- Could Quantinuum’s Breakthrough Make Its Sell-Off a Bargain?
- Wired for Upside: Why Goldman Sachs Upgraded CoreWeave’s Battered Stock
Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.
